Has Kappa Peddy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,441 in general payments to Kappa Peddy, MD across 202 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kappa Peddy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kappa Peddy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kappa Peddy, MD

Dermatology · Lynchburg, VANPI 1558315481

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 37.4% of the total.

$4,441in general payments, 2019–2025

Across 202 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Novartis$649
Incyte Corporation$293
UCB, Inc.$259
Sun Pharmaceutical Industries Inc.$250
Johnson & Johnson$239
plus $1K from 16 others

$495,691in research payments, 2019–2025

Across 92 payments — averaging $5387.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Endo Pharmaceuticals Inc.$193K
Teva Pharmaceuticals USA, Inc.$192K
Pfizer$97K
Aclaris Therapeutics, Inc.$13K
Sanofi$375

What the payments were for

Food & beverage$4,34198%
Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	65	$1,659
Novartis	35	$649
Incyte Corporation	12	$293
UCB, Inc.	12	$259
Sun Pharmaceutical Industries Inc.	14	$250
Johnson & Johnson	13	$239
Amgen	9	$218
Lilly USA, LLC	11	$211
Pfizer	7	$107
LEO Pharma Inc.	4	$97
Sanofi	4	$97
Stemline Therapeutics Inc.	1	$86
E.r. Squibb & Sons, L.L.C.	3	$59
Almirall LLC	2	$33
Arcutis Biotherapeutics, Inc.	2	$32
Boehringer Ingelheim	1	$29
Galderma Laboratories, L.p.	2	$26
Springworks Therapeutics, Inc.	1	$23
Genentech USA, Inc.	1	$22
Dermavant Sciences, Inc.	1	$20
Organon	1	$20
Prugen, Inc. Pharmaceuticals	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Humira$111
Skyrizi$102

How this compares

$4,441 in reported general payments places this provider in the 60th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia →

Medicare billing

Part B allowed, 2024

$275,481

Medicare patients

1,213

Services billed

4,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	34	$1,818
Fluorouracil	23	$1,402
Metronidazole	25	$1,149
Ciclopirox	22	$1,065
Ketoconazole	58	$1,004
Triamcinolone Acetonide	87	$752
Fluocinonide	15	$616
Minoxidil	58	$467
Doxycycline Hyclate	13	$250
Mupirocin	25	$177
Acyclovir	20	$166
Minocycline Hcl	14	$161
Nystatin	14	$143
Hydrocortisone	31	$92
MethotrexateMethotrexate Sodium	18	$68

Paid to pharmacies, not to this prescriber.

Other dermatology in Lynchburg

Naiem IssaVienna$2M
Saurabh SinghFairfax$1.7M
Diego DasilvaVirginia Beach$1.1M
Vishal PatelLeesburg$719K
Cyndi Torosky TommasoVirginia Beach$717K
Daniel HurdBlacksburg$545K
Jonathan SchreiberNorfolk$330K
Robert BaerSuffolk$303K
David PariserNorfolk$261K
Hema SundaramFairfax$181K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →